Literature DB >> 16076236

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

Vincenzo Atella1, Ellen Schafheutle, Peter Noyce, Karen Hassell.   

Abstract

INTRODUCTION: Studies have demonstrated that co-payments on medication reduce the consumption of both non-essential and essential drugs, and that the latter can lead to worse health outcomes. Far less is known about how patients cope with the cost of medication, particularly if affordability is an issue, and how this compares across two countries with different prescription charge policies. Therefore, the aim of this article is to explore empirically how, and to what extent, costs incurred by patients influence their decision-making behaviour in accessing medicines.
METHODS: Based on the findings from focus groups, a questionnaire was designed that addressed medication cost issues relevant to patients in both the UK and Italy. Using an econometric model, several hypotheses are tested regarding patients' decision-making behaviour and how it is influenced by health status, sociodemographic characteristics and the novel concept of a self-rated affordability measure.
RESULTS: Quite a large percentage of patients (70.3% in the UK and 66.5% in Italy) stated they have to think about the cost of medicines at least sometimes. Respondents adopted numerous cost-reducing strategies, subdivided into (i) those initiated by patients and (ii) those involving self-medication. Their use was strongly influenced by income and drug affordability problems, but the self-rated affordability measure was a stronger predictor. Commonly used strategies were not to get prescribed drugs dispensed at all, prioritizing by not getting all prescribed items dispensed or delaying until the respondent got paid. Furthermore, respondents with affordability issues were also cost-conscious when self-medicating with over-the-counter (OTC) products for minor conditions such as dyspepsia. Despite patients in both countries using cost-reducing strategies, their use was more pronounced in the UK, where the prescription charge was significantly higher than in Italy. DISCUSSION/
CONCLUSION: The results from this study provide detail on the kinds of strategies patients use to reduce the cost burden of prescription charges, and support previous research showing they may be foregoing essential medication. Because the same questionnaire was applied in two European countries, where the national health systems aim to provide healthcare services that are accessible to all citizens in need, it offers interesting insights for policy makers in other countries, where patients may have to pay a larger share of their drugs out-of-pocket, such as the US.

Entities:  

Mesh:

Year:  2005        PMID: 16076236     DOI: 10.2165/00148365-200504010-00005

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  13 in total

1.  Patients' Preferences for Generic and Branded Over-the-Counter Medicines: An Adaptive Conjoint Analysis Approach.

Authors:  Merja Halme; Kari Linden; Kimmo Kääriä
Journal:  Patient       Date:  2009-12-01       Impact factor: 3.883

Review 2.  The last decade of Italian pharmaceutical policy: instability or consolidation?

Authors:  Giovanni Fattore; Claudio Jommi
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 3.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 4.  Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe.

Authors:  Björn Wettermark; Brian Godman; Karolina Andersson; Lars L Gustafsson; Alan Haycox; Vittorio Bertele
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Coping strategies used by patients infected with hepatitis C virus who are facing medication costs.

Authors:  Chiranjeev Sanyal; Ethel Langille Ingram; Ingrid S Sketris; Kevork M Peltekian; Susan Kirkland
Journal:  Can J Hosp Pharm       Date:  2011-03

6.  The impact of cost-sharing schemes on drug compliance in Italy: evidence based on quantile regression.

Authors:  Vincenzo Atella; Joanna Aleksandra Kopinska
Journal:  Int J Public Health       Date:  2013-12-15       Impact factor: 3.380

7.  The implications of regional and national demographic projections for future GMS costs in Ireland through to 2026.

Authors:  Aisling Conway; Martin Kenneally; Noel Woods; Andreas Thummel; Marie Ryan
Journal:  BMC Health Serv Res       Date:  2014-10-21       Impact factor: 2.655

8.  Recruiting people facing social disadvantage: the experience of the Free Meds study.

Authors:  Pauline Norris; Kimberly Cousins; Marianna Churchward; Shirley Keown; Mariana Hudson; Leina Isno; Leilani Pereira; Jacques Klavs; Lucy Linqing Tang; Hanne Roberti; Alesha Smith
Journal:  Int J Equity Health       Date:  2021-06-29

9.  Is 50 cent the price of the optimal copayment? - a qualitative study of patient opinions and attitudes in response to a 50 cent charge on prescription drugs in a publicly funded health system in Ireland.

Authors:  Sarah-Jo Sinnott; Marie Guinane; Helen Whelton; Stephen Byrne
Journal:  BMC Health Serv Res       Date:  2013-01-10       Impact factor: 2.655

10.  Can differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2.

Authors:  John Larsen; Henrik Stovring; Jakob Kragstrup; Dorte G Hansen
Journal:  BMC Public Health       Date:  2009-05-16       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.